Literature DB >> 24477111

High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women.

Laure Carcaillon1, Sylvie Brailly-Tabard, Marie-Laure Ancelin, Olivier Rouaud, Jean-François Dartigues, Anne Guiochon-Mantel, Pierre-Yves Scarabin.   

Abstract

OBJECTIVE: We aimed to investigate the impact of endogenous estradiol (E2) on dementia and to evaluate the contribution of vascular risk factors and inflammatory and blood coagulation markers to this association.
METHODS: Using data from a French population-based prospective study (the Three-City Study) including 5,644 postmenopausal women aged 65 years or older, we investigated the association of endogenous total-E2 and bioavailable-E2 and total-testosterone with the 4-year incidence of all-cause dementia. We further focused on the role of dementia and cardiovascular risk factors as well as inflammation (C-reactive protein, fibrinogen) and hypercoagulability (fibrin d-dimers, thrombin generation) in these associations. We used a case-cohort design consisting of a random subcohort of 562 women not using hormone therapy and 132 incident dementia cases.
RESULTS: Adjusted Cox proportional hazards models showed a J-shaped relationship between total-E2 and risk of dementia (p = 0.001). Total-E2 values in the lower and upper quartiles were associated with an increased dementia risk (adjusted hazard ratio [HR] [95% confidence interval] = 2.2 [1.1-4.5] and HR = 2.4 [1.2-5.2], respectively). Importantly, the risk associated with higher E2 levels was dramatically increased in women with diabetes compared with nondiabetic women (adjusted HR associated with the upper E2 quartile = 14.2 [1.60-123] and HR = 3.4 [0.1-147], respectively, p interaction <0.05). Similar results were found for bioavailable-E2. Adjustment for inflammatory and blood coagulation markers did not modify our results. No significant association was found for total-testosterone.
CONCLUSION: High E2 level is an independent predictor of incident dementia, particularly in postmenopausal women with diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477111     DOI: 10.1212/WNL.0000000000000107

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Postmenopausal hormone therapy and cognition.

Authors:  Anna C McCarrey; Susan M Resnick
Journal:  Horm Behav       Date:  2015-04-30       Impact factor: 3.587

2.  Microvascular lesions by estrogen-induced ID3: its implications in cerebral and cardiorenal vascular disease.

Authors:  Jayanta K Das; Quentin Felty
Journal:  J Mol Neurosci       Date:  2014-08-17       Impact factor: 3.444

3.  Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.

Authors:  Mark A Espeland; Roberta Diaz Brinton; JoAnn E Manson; Kristine Yaffe; Christina Hugenschmidt; Leslie Vaughan; Suzanne Craft; Beatrice J Edwards; Ramon Casanova; Kamal Masaki; Susan M Resnick
Journal:  Neurology       Date:  2015-07-10       Impact factor: 9.910

4.  Endogenous sex hormones and cognitive function in older women.

Authors:  Alain K Koyama; Shelley S Tworoger; A Heather Eliassen; Olivia I Okereke; Marc G Weisskopf; Bernard Rosner; Kristine Yaffe; Francine Grodstein
Journal:  Alzheimers Dement       Date:  2016-01-21       Impact factor: 21.566

Review 5.  Neuroactive Steroids and Sex-Dimorphic Nervous Damage Induced by Diabetes Mellitus.

Authors:  Silvia Giatti; Silvia Diviccaro; Roberto Cosimo Melcangi
Journal:  Cell Mol Neurobiol       Date:  2018-08-14       Impact factor: 5.046

Review 6.  Interactions between estradiol, diabetes, and brain aging and the risk for cognitive impairment.

Authors:  C E Hugenschmidt; T Duran; M A Espeland
Journal:  Climacteric       Date:  2021-02-15       Impact factor: 3.024

7.  Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.

Authors:  Mark A Espeland; Roberta Diaz Brinton; Christina Hugenschmidt; JoAnn E Manson; Suzanne Craft; Kristine Yaffe; Julie Weitlauf; Leslie Vaughan; Karen C Johnson; Claudia B Padula; Rebecca D Jackson; Susan M Resnick
Journal:  Diabetes Care       Date:  2015-10-20       Impact factor: 19.112

Review 8.  Gaps in menopause knowledge.

Authors:  Sun Kyoung Yum; Tak Kim
Journal:  J Menopausal Med       Date:  2014-08-27

9.  Effects of evolocumab therapy and low LDL-C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes.

Authors:  Dirk J Blom; Jiyan Chen; Zuyi Yuan; Joao L C Borges; Maria L Monsalvo; Nan Wang; Andrew W Hamer; Junbo Ge
Journal:  Endocrinol Diabetes Metab       Date:  2020-03-06

Review 10.  Diverse pathomechanisms leading to the breakdown of cellular estrogen surveillance and breast cancer development: new therapeutic strategies.

Authors:  Zsuzsanna Suba
Journal:  Drug Des Devel Ther       Date:  2014-09-11       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.